Blueprint Medicines
About
Blueprint Medicines is a Cambridge biopharmaceutical company working to advance a deep pipeline of precision therapies designed to help patients live longer, healthier lives. Its approach combines expertise in protein kinases, enzymes that can drive disease when altered, with sound execution and an intense focus on discovery. The company is moving multiple investigational medicines through clinical development for patients with a broad range of genomically defined cancers and rare diseases.
Blueprint’s best-known product is Ayvakit, known generically as avapritinib, an approved kinase inhibitor that treats certain forms of gastrointestinal stromal tumor as well as systemic mastocytosis, a rare disorder of mast cells. The drug reflects the company’s model of matching precise kinase-targeted medicines to diseases defined by specific genetic drivers, an approach it continues to apply across a diverse and growing set of research programs.
What to Know
- In 2025 the company was acquired by the French drugmaker Sanofi.
- Blueprint is listed with the Cambridge Chamber of Commerce.
- It is also listed with the Central Square Business Improvement District.
Is this your business?
Claim it to add hours, photos, a description and a spotlight story.